9th Conference of the European Hidradenitis Suppurativa Foundation
5-7 February 2020

“In-depth understanding of HS meets philosophical stochaism”

Under the auspices of

Conference Venue
Divani Caravel Hotel, Athens
We fight the toughest challenges with advanced science.

At AbbVie, we put our passion to work where the need is greatest. Because our purpose as a global biopharmaceutical company is to make a remarkable impact on peoples lives.

It takes all of us to turn possibilities into medicine that reaches millions. So we partner with governments, academic institutions, and scientific and advocacy groups to make it happen. Together, we’re inventing the future of medicine.

Learn more at abbvie.com

AbbVie

People, Passion. Possibilities.
A message from the Organizers,

Hidradenitis suppurativa (HS) is a debilitating skin disorder that destroys not only skin areas rich in apocrine glands but, and most importantly, human lives of young people rendering them incapable to enjoy life and entering them into a vicious cycle of daily restriction and lack of function and loss of life appetite. Our boundaries in the management of HS are coming from our incomplete understanding of pathogenesis. It is obvious that further steps in HS cannot only come from fancy –omics technologies but, mainly, from using the skills that have been founded in Medicine from our ancient ancestors; listening to the patients describing symptoms and feelings; close observation of clinical findings; and critical thinking.

We are very proud to welcome you in our capital city Athens for the 9th Conference of the European Hidradenitis Suppurativa Foundation. Our target for this conference is how philosophical stochaism for a disease, exactly as described in Hippocrates books, can assist in our in-depth understanding of the mechanisms of HS leading to better patient management. To achieve so, all Greek experts in dermatology, immunology and skin infections are joining their forces. Our work has brought major advances in the HS field at an international level though ground-breaking publications in the field of immunology and genetics and though our participation in large-scale trials. We seek to provide, in collaboration with the European Hidradenitis Suppurativa Foundation, the best possible educational program. We are also warmly endeavored to acquaint you with our famous Greek hospitality.

Dimitris Rigopoulos, MD, PhD
Professor of Dermatology
Chairman and Director “A.Sygros” hospital

Evangelos J. Giamarellos-Bourboulis, MD, PhD
Professor of Internal Medicine
Dear Colleagues,

Hidradenitis suppurativa / acne inversa (HS) has been until 2006 an orphan disease. Many aspects have changed since then to the better, thanks to the joint contributions of dedicated colleagues around the globe. However, the delay of diagnosis of 7.2 years published by Saunte et al. in 2015 on 517 patients from 24 countries reveals that, despite the rapid progress in scientific knowledge and treatment measurements, a lot has still to be done to improve the course of this debilitating disease and the life quality of diseased fellows at their most productive age.

The inauguration of the Hidradenitis Suppurativa Foundation, Inc. in 2005 and the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) in 2012 and the organization of international thematic conferences, in Dessau, Germany (2006), San Francisco, IL, USA (2009), Brussels, Belgium (2014 and 2015), Berlin, Germany (2016), Copenhagen, Denmark (2017), Rotterdam, The Netherlands (2018) and Wroclaw, Poland (2019) have been milestones for dissemination of knowledge. They resulted in products of international clinical cooperation, such as the consensus definition of the disease, the diagnostic criteria and the national and European guidelines for treatment as well as the inclusion of HS to the diseases, whose harmonization of care is targeted by the European Reference Networks for Rare and Complex Skin Diseases (ERN Skin). In addition to the clinical progress, the scientific interest to the disease has rapidly increased and the scientific work performed by clinician and scientists has grown exponentially. Patients have been organized in several self-aid groups. A first compound for medical treatment has been registered and more are currently studied in dermatological departments worldwide.

The EHSF e.V. grows up with every conference, which provides significant information to the scientific and lay community at an annual basis. In 2020, the EHSF e.V. is going to visit the historic city of Athens. A specialists' team from the National and Kapodistrian University of Athens and the Aristotle University of Thessaloniki overtake the local organization...
of the 9th International Conference in February 5-7, 2020. It will offer a
great opportunity to deepen into current HS research and summarize the
developments, which occurred in HS during the last, exciting year. The
better understanding of HS pathophysiology and the actualization of the
guidelines for HS treatment but also first results of the ongoing clinical
studies and the targets for the years to come will be the central subjects of
this scientific event. In parallel, EHSF e.V. opens its doors to the
representatives of specialized nurses working groups and invites all caring
physicians and scientists, independently of their specialization, to
participate, since the emerging comorbidity of HS requires an
interdisciplinary approach.

As EHSF e.V. president, I am fascinated for what we have reached
together and for the growing speed of our Society. I am honoured and
pleased to invite you to the 9th International Conference of the EHSF e.V.
in Athens. We plan to construct a scientific programme of high impact
providing current information on research and its clinical relevance on HS
and speakers selected among you, who are going to submit abstracts,
attracting both experts in the field and motivating upcoming specialists to
participate, but also young scientists and students working or wishing to
work in this fascinating field in the future and the partners of the
pharmaceutical industry, who are active in the field. During the Conference
you will have the opportunity to share your knowledge and perspectives
and also gain a better insight into HS by discussing with experts. At last but
not least, you will reactivate old friendships and obtain the opportunity to
develop new ones.

I have no doubt that the 9th International EHSF Conference will
become an unforgettable experience, especially since our local hosts are
overtaking superb efforts to satisfy our networking wishes and to present
you Athens and its Greek hospitality.

I look forward to address you a friendly welcome to
Athens and thank you in advance for joining us in the 9th
International Conference of the EHSF e.V.
On behalf of the Organizing and Scientific Programme
Committees

Prof. Dr. med. Prof. honoraire Dr. h.c. Christos C. Zouboulis, Dessau
President of the EHSF e.V.
Local organizing committee

Co-chairs:

Prof. Dimitris Rigopoulos  
Prof. Evangelos J. Giamarellos-Bourboulis

General Secretary

Prof. Alexandros Stratigos

Members

Prof. Dimitrios Ioannides  
Prof. Electra Nikolaidou  
Prof. Alexander Katoulis  
Prof. Evangelia Papadavid  
Dr. George Kontochristopoulos  
Dr. Fragkiski Tsatsou  
Dr. Aikaterini Liakou  
Dr. Anastasia Trigoni
International Scientific Committee

Vincenzo Bettoli (Italy)
Arnon D. Cohen (Israel)
Veronique Del Marmol (Belgium)
Lennart Emtestam (Sweden)
Evangelos J. Giamarellos-Bourboulis (Greece)
Philippe Guillem (France)
Wayne Gulliver (Canada)
Barbara Horváth (The Netherlands)
Evgeniya Hristakieva (Bulgaria)
Robert Emil Hunger (Switzerland)
John Ingram (UK)
Gregor BE Jemec (Denmark)
Alexander Katoulis (Greece)
Brian Kirby (Ireland)
Antonio Martorell-Calatayud (Spain)
Angelo Valerio Marzano (Italy)
Lukasz Matusiak (Poland)
Aude Nassif (France)
Errol P Prens (The Netherlands)
Marco Romanelli (Italy)
Ditte Marie Saunte (Denmark)
Jacek Szepietowski (Poland)
Skaidra Valiukevičienė (Lithuania)
Thrasyvoulos Tzellos (Norway)
Hessel han der Zee (The Netherlands)
Christos C Zouboulis (Germany)
Our vision: ACHIEVE

National and Kapodistrian University of Athens
Birthplace of our:
  • Humanitarian thinking
  • Clinical reasoning
  • Investigational instinct
For Patients with HS

INTERACTION

• Advance new research ideas
• Collaborate in all fields of expertise
• Highlight recent developments
• Improve patient care
• Vision hope for patients
• Enhance new therapies
The scientific programme at a glance:

Wednesday February 5th 2019 (Olympia Hall)
11:00-13:00 Hidradenitis suppurativa nursing school
13:00-15:00 Industry workshop
16:00-16:30 Welcome addresses (National & Kapodistrian University of Athens)
16:30-18:00 Plenary session

Thursday February 6th 2019 (Olympia Hall)
08:00-09:00 General Assembly EHSF
09:00-10:30 Immunology
11:30-13:00 Endpoints of clinical trials
14:00-15:00 Poster presentations at poster area (Ilissos Hall)
15:00-16:30 Genetic and molecular profiling
16:30-18:00 Medical treatment

Friday February 7th 2019 (Olympia Hall)
09:00-10:30 Epidemiology and diagnostic tools
11:00-12:30 Industry Satellite Symposium
13:30-15:00 News from clinical trials
15:30-16:30 Surgical treatment
16:30-17:25 Open panel discussion: what novelty is required to move the field forward?
17:15-17:40 Hidradenitis suppurativa around the world
17:30-17:40: Adieu
11:00-13:00 *Hidradenitis suppurativa nursing school (Olympia Hall)*

**Chairs:** Véronique del Marmol (Belgium), Shani Fisher (Israel), Wayne Gulliver (Canada)

11:00-11:15 The need of nurses for the management of HS  
*Véronique del Marmol (Belgium)*

11:15-11:30 How to manage flare-ups  
*Barbara Horváth (The Netherlands)*

11:30-11:45 Prioritizing patients’ needs  
*Alexandra Poinas (France)*

11:45-12:00 Working disability in patients with HS  
*Anastasia Trigoni (Greece)*

12:00-12.15 The multidisciplinary approach in HS care  
*Stephanie R Goldberg (USA)*

12:15-12:30 The role of the study nurse for clinical trials  
*Amalia Bolanou (Greece)*

12:30-12:45 The need for networking  
*Shani Fisher (Israel)*

12:45-12:50 Commentary  
*Tryfon Papadopoulos (Greece)*

12:50-13:00 Discussion
13:00-15:00 Sponsored workshop

*Integrated Medical & Surgical Treatment in HS (Olympia Hall)*
(see pg44 for details)

**Plenary program and Opening ceremony**

*Auditorium of the Old Building of the National and Kapodistrian University of Athens* (bus transfer from Divani Caravel Hotel at 15:15)

**16:00-16:30 Welcome addresses**

**Prof. Meletios-Athanassios Dimopoulos** Rector of the National and Kapodistrian University of Athens  
**Prof. Petros P Sfikakis** Dean of the Medical School of the National and Kapodistrian University of Athens  
**Prof. Christos C Zouboulis** President of the EHSF eV  
**Prof. Dimitris Rigopoulos** Co-chair of the local Organizing Committee  
**Prof. Evangelos J Giamarellos-Bourboulis** Co-chair of the local Organizing Committee

**16:30-18:00 Plenary session**

Chairs: Christos C Zouboulis (Germany), Alexander Stratigos (Greece)

16:30-17:00 New pathways for medical treatment: the complement paradigm  
*Evangelos J Giamarellos-Bourboulis (Greece)*

17:00-17:30 My life career: the fight against HS  
*Jean Révuz (France)*

17:30-18:00 Choose your adversary with care - and help the sick  
*Gregor BE Jemec (Denmark)*

**18:00-20:00 Social program and reception at Kostis Palamas building** (Guided walk from the old building.)
Thursday February 6th 2019

08:00-09:00 General Assembly EHSF (Olympia Hall)

09:00-10:30 Immunology (Olympia Hall)

Chairs: Lennart Emtestam (Sweden), Aude Nassif (France)

09:00-09:15 HS as an innate immune disorder
Errol P Prens (The Netherlands)

09:15-09:30 HS as an adaptive immune disorder
Aikaterini I Liakou (Greece)

09:30-09:45 The impact of nutrition on inflammation
Joi Lenczowski (USA)

09:45-10:00 Non-invasive assessment of cytokine and antimicrobial peptide levels in HS using transdermal analysis patches
Kelsey R van Straalen (The Netherlands)

10:00-10:15 Investigations on the prevalence of inflammatory bowel diseases in patients with hidradenitis suppurativa
Krisztian Gaspar (Hungary)

10:15-10:30 Discussion

10:30-11:30 Coffee break and poster walk (Olympia & Ilissos Exhibition Hall)
11:30-13:00 Endpoints of clinical trials (Olympia Hall)

This session will be recorded and proceedings of the presentations will be published in a supplementary volume of *Experimental Dermatology*

Chairs: Gregor BE Jemec (Denmark), Christos C Zouboulis (Germany)

11:30-11:45  I love HiSCR  
*Brian Kirby (Ireland)*

11:45-12:00  We need to move onwards: the IHS4 paradigm  
*Thrasyvoulos Tzellos (Norway)*

12:00-12:15  What patient reported outcomes do we really need?  
*John Ingram (UK)*

12:15-12:30  The outcome measure may vary by the drug mechanism of action  
*Wayne Gulliver (Canada)*

12:30-12:45  What should be the outcome measure after surgery?  
*Maurizio Podda (Germany)*

12:45-13:00  Discussion

13:00-14:00  Lunch break (Olympia & Illissos Exhibition Hall)

14:00-15:00  Poster presentations at poster area (Illissos Hall)  
All abstracts accepted as either oral or ePoster presentations will be published in a supplementary volume of *Experimental Dermatology*
Posters will be presented as e-Posters. ePosters are classified according to the thematic area. One chairperson is appointed per thematic area. Chairpersons, authors and attendees will walk through the posters per thematic area where each author will be given 3 minutes for a brief on site oral presentation of his/her work. An award committee will collaborate with the chairpersons to grade the ePosters.

*Discussions taking place with the authors during all four poster walks will be taken into consideration.* The top three ePosters will be awarded.

**ePoster awards will be:**
- **First Award:** award certificate + financial grant €1,000 as waiver fee for EHSF2021 and one 15-minute oral presentation of abstract submitted at EHSF2021
- **Second Award:** award certificate + financial grant €600 as waiver fee for EHSF2021 and one 15-minute oral presentation of abstract submitted at EHSF2021
- **Third Award:** award certificate + financial grant €400 as waiver fee for EHSF2021 and one 15-minute oral presentation of abstract submitted at EHSF2021

Awards will be announced during the closing ceremony.

The chairpersons per topic will be:
- **Epidemiology (screen Plato): Stamatis Gregoriou (Greece)**
- **Epidemiology and Imaging (screen Aristotle): Antonio Martorell-Calatayud (Spain)**
- **Nursing (screen Galenus): Shani Fisher (Israel)**
- **Immunology (screen Socrates): Vassiliki Tzanetakou (Greece)**
- **Genetics and novel treatments (screen Epicurus): Theodora Kanni (Greece)**
- **Medical treatment I (screen Asklepios): George Kontochristopoulos (Greece)**
Medical treatment II (screen Hippocrates):
Ditte Marie Saunte (Denmark)
Outcome measures I (screen Heraclitus):
Skaidra Valiukevičienė (Lithuania)
Outcome measures II (screen Democritus):
Evgeniya Hristakieva (Bulgaria)
Comorbidities I (screen Thales): Anastasia Trigoni (Greece)
Comorbidities II (screen Pythagoras): Fragkiski Tsatsou (Greece)

15:00-16:30 Genetic and molecular profiling* (Olympia Hall)

Chairs: Elisabeth Lazaridou (Greece), Lukasz Matusiak (Poland)

15:00-15:15 Available evidence: an overview
Robert Emil Hunger (Switzerland)

15:15-15:30 Pathogens or commensals? Bacteriology unraveled
Alexandros Katoulis (Greece)

15:30-15:45 Innate immunity and epithelial cell differentiation are altered in hidradenitis suppurativa
Christos C Zouboulis (Germany)

15:45-16:00 Association between changes of the IHS4 score following adalimumab treatment with carriage of single nucleotide polymorphisms of the TNF gene
Maria Argyropoulou (Greece)

16:00-16:15 Targeted gene panel sequencing for hidradenitis suppurativa in patients from a Southern European Area
Lorena Barboza-Guadagnini (Spain)

16:15-16:30 Discussion

*Coffee and light snacks are served in the room
16:30-18:00 Medical treatment* (Olympia Hall)

Chairs: Dimitris Rigopoulos (Greece), Marco Romanelli (Italy)

16:30-16:45 All depends on antibiotics
   Vincenzo Bettoli (Italy)

16:45-17:00 What a large European cohort suggests on the efficacy of antibiotics
   Hessel H van der Zee (The Netherlands)

17:00-17:15 Efficacy and safety results from the SHARPS Study: Phase 4, randomized, controlled trial of adalimumab plus surgery in moderate-to-severe hidradenitis suppurativa
   Falk G Bechara (Germany)

17:15-17:30 Decrease of purulence by IFX-1 in severe hidradenitis suppurativa: an analysis using matched comparators
   Theodora Kanni (Greece)

17:30-17:45 Hidradenitis suppurativa management using TNF inhibitors in patients under the age of 18: a series of 12 cases
   Anne-Claire Fougerousse (France)

17:45-18:00 Discussion
   *Coffee and light snacks are served in the room

19:00-22:00 Visit and dinner at the Acropolis museum
   (bus transfer from Divani Caravel Hotel at 18:15)
   The official conference dinner will be hosted at the Acropolis museum. Guided tour will be provided.
Friday February 7th 2019

09:00-10:30 Epidemiology and diagnostic tools (Olympia Hall)

Chairs: Véronique Del Marmol (Belgium), Angelo Valerio Marzano (Italy)

09:00-09:15 Focus on geographic variations and financial impact
Arnon D Cohen (Israel)

09:15-09:30 HISTORIC collaboration
Amit Garg (USA)

09:30-09:45 Skin ultrasound as classification tool
Ximena Wortsman (Chile)

09:45-09:45 Do itch and pain affect sleep in hidradenitis suppurativa patients? A comparison to other chronic inflammatory skin diseases
Karolina Kaaz (Poland)

09:55-10:05 A clinico-epidemiological study of HS patients in a reference center in Northern Greece
Styliani Siskou (Greece)

10:05-10:15 Hidradenitis suppurativa in Sweden: a registry-based cross-sectional study of 13538 patients
Lennart Emtestam (Sweden)

10:15-10:30 Discussion

10:30-11:00 Coffee break and poster walk
(Olympia & Ilissos Exhibition Hall)
11:00-12:30 Industry satellite symposium (Olympia Hall)
(see pg45 for details)

12:30-13:30 Lunch break (Olympia & Ilissos Exhibition Hall)

13:30-15:00 News from clinical trials (Olympia Hall)

Chairs: Jacek Szepietowski (Poland), Electra Nicolaidou (Greece)

13:30-13:45 Efficacy and safety of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, for the treatment of moderate-to-severe hidradenitis suppurativa (HS): a 12-week, randomised, double-blind, placebo-controlled, phase 2 study
Gregor BE Jemec (Denmark)

13:45-14:00 Long-term benefit of the monoclonal anti-C5a antibody IFX-1 in patients with moderate to severe hidradenitis suppurativa: Results of open label extension period of the Phase IIb SHINE study
Evangelos J Giamarellos-Bourboulis (Greece)

14:00-14:15 Improvement in Hidradenitis Suppurativa (HS) and Quality of Life (QoL) in patients treated with adalimumab: Real-world results from the HARMONY Study
Ariela Hafner (Israel)

14:15-14:30 Improvement of the quality of life of patients with moderate to severe hidradenitis suppurativa treated with adalimumab: The SOLACE study final analysis
Wayne Gulliver (Canada)
14:30-14:45 Pain in hidradenitis suppurativa
   Georgios Kokolakis (Germany)

14:45-15:00 Discussion

15:00-15:30 Coffee break and poster walk (Olympia & Ilissos Exhibition Hall)

15:30-16:30 Surgical treatment (Olympia Hall)

   Chairs: Michelle Lowes (USA), Evangelia Papadavid (Greece)

15:30-15:45 Where do we stand?
   Stephanie R Goldberg (Richmond, USA)

15:45-16:00 High full remission rate of hidradenitis suppurativa treated with wide margin excision and secondary healing after three years of follow-up
   Evgeniya Hristakieva (Bulgaria)

16:00-16:15 Ultrasound-guided injection of intralesional steroids in acute lesions of hidradenitis suppurativa: a prospective study
   Micheal Iannone (Italy)

16:15-16:30 Discussion
16:30-17:30  Closing ceremony (Olympia Hall)

16:30-17:25  Open panel discussion: what novelty is required to move the field forward?

Chair: Dimitrios Ioannides (Greece)

Participants: Afsaneh Alavi (Canada), Evangelos J Giamarellos-Bourboulis (Greece), Gregor BE Jemec (Denmark), Michelle Lowes (USA), Christos C Zouboulis (Germany)

Each participant has 5 minutes to make his statement.

17:15-17:40  Hidradenitis suppurativa around the world

17:15-17:20  Hidradenitis suppurativa: epidemiological study of cases diagnosed at the dermatology unit of the Bonsucesso Federal Hospital, Brazil
Felipe Soeiro (Brasil)

17:20-17:25  Survey of patients' quality of life with hidradenitis suppurativa in Japan
Koremasa Hayama (Japan)

17:25-17:30  Hidradenitis suppurativa prevalence in Berekum, Ghana – initial validation of a HS questionnaire in an African setting
Paa Gyasi Hagan (Ghana)

17:30-17:40  Adieu
Evangelos J Giamarellos-Bourboulis (Greece), Christos C Zouboulis (Germany)
Hidradenitis suppurativa: results of the register of morbidity and use of health resources in the autonomous community of Catalonia, Spain (abstract ID 30)
Jorge Romaní (Spain), Assumpta Ricart, Jesús Luelmo

Hidradenitis suppurativa: epidemiological study of cases diagnosed at the dermatology unit of the Bonsucesso Federal Hospital, Brazil (abstract ID 37)
Suellen Ramos de Oliveira (Brazil) Caroline Monteiro, Maiara Beber, Livia Barbosa, Felipe Soeiro

Evaluating patients' unmet needs in hidradenitis suppurativa: results from the global VOICE project (abstract ID 47)
Amit Garg (USA), Erica Neuren, Denny Cha, Joslyn S Kirby, John R Ingram, Gregor BE Jemec, Solveig Esmann, Linnea Thorlacius, Bente Villumsen, Véronique del Marmol, Aude Nassif, Maia Delage, Thasyvoulos Tzellos, Dagfinn Moseng, Øystein Grimstad, Haley Naik, Robert Micheletti, Sandra Guilbault, Angie Parks Miller, Iltefat Hamzavi, Hessel van der Zee, Errol Prens, Naomi Kappe, Christine Ardon, Brian Kirby, Rosalind Hughes, Christos C Zouboulis, Georgios Nikolakis, Falk G Bechara, Lukasz Matusiak, Jacek Szepietowski, Amelia Glowaczewska, Saxon D Smith, Noah Goldfarb, Steven Daveluy, Christina Avgoustou, Evangelos J Giamarellos-Bourboulis, Steven Cohen, Yssra Soliman, Elena Gonzalez Brant, Oleg Akilov, Christopher Sayed, Jerry Tan, Afsaneh Alavi, Michelle A Lowes, José C Pascual, Hassan Riad, Shani Fisher, Arnon Cohen, So Yeon Paek, Barry Resnik, Qiang Ju, Langi Wang, Andrew Strunk, Shari Wright
Survey of patients’ quality of life with hidradenitis suppurative in Japan (abstract ID 52)
Koremasa Hayama (Japan) Hideki Fujita, Takashi Hashimoto, Tadashi Terui

HiSQOL – a validation of a HS specific quality of life questionnaire (abstract ID 59)
Christoffer Kursawe Larsen (Denmark) Rune Kjærsgaard Andersen, Ditte Marie Saunte, Gregor BE Jemec

The broad-spectrum impact of hidradenitis suppurativa on quality of life (abstract ID 66)
Francesca Sampogna, Luca Fania, Simona Mastroeni, Biagio Didona, Damiano Abeni

Hidradenitis suppurativa prevalence in Berekum, Ghana – initial validation of a HS questionnaire in an African setting (abstract ID 73)
Paa Gyasi Hagan (Ghana), Rune Kjærsgaard Andersen, Inge EJ ten Seldam, Fleu van Gelder, Ceren M Zwijnenburg, Jurr Boer, Gregor BE Jemec

Number of diagnoses based on number of publications (abstract ID 78)
Rune Kjærsgaard Andersen (Denmark), Dorra Bouazzi, Friis Jørgensen, Søren Brunak, Gregor BE Jemec

Pediatric hidradenitis suppurativa in Germany (abstract ID 84)
Christos C Zouboulis (Germany) Georgios Nikolakis, Aristeidis Vaiopoulos

Coping with HS or Psoriasis- qualitative study (abstract ID 88)

Creation of a patient database for participation in the European register of hidradenitis suppurativa / acne inversa (ERHS) (abstract ID 89)
Hendrik Hansen (Germany), Georgios Nikolakis, Christos C Zouboulis
Vulvar hidradenitis suppurativa: an under-diagnosed agony. Clinical and ultrasonographycal study of 25 patients (abstract ID 29)
Jorge Romaní de Gabriel (Spain) Cristina López Llunell, Patricia Garbayo, Jesús Luelmo

Infrared thermography and sonography combination for inflammation evaluation in hidradenitis suppurativa patients (abstract ID 53)
Vaiva Jariene (Lithuania) Skaidra Valiukeviciene, Renaldas Raisutis, Vincentas Veikutis, Erika Pauseika, Vesta Kucinsiene

Clinical and ultrasonographic phenotypic characterization of hidradenitis suppurativa: experience of a single Italian center (abstract ID 56)
Antonella Di Cesare (Italy) Elia Rosi, Federica Ricceri, Leonardo Pescitelli, Maria Thais Fastame, Francesca Prignano

Hidradenitis suppurativa treatment with intense pulsed light – A within-person randomized controlled trial (abstract ID 75)
Pernille Lindsø Andersen (Denmark) Peter Theut Riis, Linnea Thorlaci, Viktoria Sigsgaard, Christina Wilken Nielsen, Lana Chafraenska, Christine Westergaard, Gregor BE Jemec, Ditte Marie Saunte

Impact of hidradenitis suppurativa in employment status: a cross-sectional study (abstract ID 97)
Lorena Barboza-Guadagnini (Spain) Sebastian Podlipnik, Julio Bassas-Vila

Race-specific prevalence of hidradenitis suppurativa: a systematic review (abstract ID 126)
Muskaan Sachdeva (Canada) Monica Shah, Afsaneh Alavi
“EDUDERM” patient therapeutic education: a key player in the COVER cohort (abstract ID 140)
Alexandra Poinas (France) Florence Vrignaud, Emilie Varey, Marie LeMoigne, Sarah Le Naour, Domitille Jorand-Bauer, Françoise Elan, Laetitia Menneron, S Blot, Isabelle Gauvrit, Jean-Michel Nguyen, Amir Khammari, Brigitte Dreno

Magnetic resonance findings in long standing intergluteal hidradenitis supurativa (abstract ID 141)
Maria Cecilia Rivitti-Machado (Brazil)

Hidradenitis suppurativa in the pediatric population: preliminary data from a retrospective clinical study (abstract ID 146)
Simone Garcovich (Italy) Luca Fania, Raffaele Dante Caposiena Caro, Giulia Giovanardi, Andrea Chiricozzi, Chiara Tartaglia, Davide Ciccone, Luca Bianchi, Damiano Abeni, Ketty Peris

Work productivity among hidradenitis suppurativa patients and associated risk factors (abstract ID 166)
Kelsey R van Straalen (The Netherlands), Lisette M Prens, Hessel H van der Zee, Tjerk H Hylkema, Sandra Brouwer, Errol P Prens, Barbara Horváth

Hidradenitis suppurativa in children and adolescents: A clinical review of thirty cases (abstract 169)
Efthymia Agiasofitou (Greece) Georgios Kontochristopoulos, Anastasia Kapsiocha, Vassiliki Tzanetakou, Kleoniki Pantelidi, Aikaterini I Liakou, Ioannis Marelakis, Nikolaos Rotsiamis, Dimitris Rigopoulos
Use of internet by hidradenitis suppurativa patients: an observational study Resoverneuil.net (abstract ID 60)
Anne-Claire Fougerousse (France), Germaine Gabison, Anne-Cécile Ezanno, Jean-Luc Perrot, Juliette Delaunay, Ziad Reguiai, Francois Maccari, Philippe Guillem

Which disease-related messages would patients with hidradenitis suppurativa tattoo on their skin? (abstract ID 70)
Philippe Guillem (France)

Which factors are identified by the patients as influencers of hidradenitis suppurativa? (abstract ID 71)
Farida Benhadou (France), Axel P. Villani, Virginie Vlaeminck-Guillem, Philippe Guillem

Emergency doctor’s ability to diagnose hidradenitis suppurativa (abstract ID 77)
Dorra Bouazzi (Denmark) Peter Theut Riis, Ditte Marie Lindhardt Saunte, Gregor BE Jemec

Hidradenitis suppurativa with male genital involvement: a possible clinical marker of higher severity? (abstract ID 80)
Raffaele Dante Caposiena Caro (Italy) Elisa Molinelli, Andrea Sechi, Marina Venturini, Valerio Brisigotti, Chiara Tartaglia, Annamaria Offidani, Annalisa Patrizi, Beatrice Raone, Piergiacomo Calzavara-Pinton, Luca Bianchi
**Hidradenitis Suppurativa on Facebook: Thematic and content analyses of patients support group (abstract ID 87)**
Shani Fisher (Israel), Ayelet Jehassi, Michael Ziv

HS is considered to be an undertreated, misunderstood, time-consuming and cost-intensive disease by most patients: A survey by online, self-completed questionnaires among 1301 subjects in Greece (abstract ID 95)
Aikaterini I Liakou (Greece) Georgios Kontochristopoulos, Ioannis Marelakis, Antigoni Alevizou, Marios Papadakis, Nikolaos Rotsiamis, Dimitris Rigopoulos

**Psychological support for hidradenitis suppurativa: semi-directive interview to assess psychological trait and psychosomatic aspects (abstract ID 101)**
Ermina Odidou (France), Nathalie Dumet, Philippe Guillem

**Suicide in a patient diagnosed with hidradenitis suppurativa after missed follow-up appointments: A literature review and call for action (abstract ID 127)**
Muskaan Sachdeva (Canada) Monica Shah, Roger S McIntyre, Afsaneh Alavi

**The role of a clinical research nurse in the management team of hidradenitis suppurativa: focusing on clinical trials (abstract ID 136)**
Amalia Bolanou (Greece) Vassiliki Tzanetakou, Theodora Kanni, Dimitra Stergianou, Evangelos J Giamarellos-Bourboulis
In silico analysis of gamma-secretase-complex mutations in hidradenitis suppurativa demonstrates disease-specific substrate recognition and cleavage alterations (abstract ID 31)
John W Frew (USA) Kristina Navrazhina

Could VEGF blockade induce hidradenitis suppurativa? Report of three patients with renal cancer treated with sunitinib (abstract ID 38)
Trinidad Montero-Vilchez (Spain) Ahinoa Bueno-Rodriguez, Manuel Sanchez-Diaz, Andrea Rodriguez-Tejero, Salvador Arias-Santiago, Alejandro Molina-Leyva

Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa (abstract ID 44)
Yonghao Cao (USA), Feng Hong, Donna Conlon, Lauren Sidur, Kathleen Smith, Yuni Fang, Carolyn Cuff, Zehra Kaymakcalan, Melanie Ruzek

Classification of hidradenitis suppurativa in two phenotypes with two-step cluster analysis, including presence of gamma-secretase mutations, interleukin-1, interleukin-10, interleukin-17, interleukin-6, C-reactive protein and clinical pattern (abstract ID 46)
Eugènia Agut-Busquet (Spain), Jorge Romaní, Elisabet Cantó, Anna Mensa, Juan I Aróstegui, Silvia Vidal

Apocrine glands are bystanders in hidradenitis suppurativa with a gender-specific involvement pattern (abstract ID 83)
Christos C Zouboulis (Germany) Sabine Fimmel, Konstantin C Zouboulis
Identification of highly potent and selective Interleukin-1 receptor associated kinase 4 (IRAK4) degraders for the treatment of hidradenitis suppurativa (abstract ID 86)
Anthony Slavin (USA) Veronica Campbell, Haojing Rong, Michele Mayo, Xiao Zhang Zheng, Nan Ji, Matt Weiss, Chris de Savi, Scott Rusin, Kirti Sharma, Jared Gollob, Nello Mainolfi

Increased frequencies of innate lymphoid cells in patients with hidradenitis suppurativa (abstract ID 98)
Anna Malara (Ireland) Jana Musilova, Roisin Hambly, Rosalind Hughes, Peter Doran, Brian Kirby

Immuno-metabolic alterations in Hurley stage 1 hidradenitis suppurativa (abstract ID 114)
Maïa Delage (France) Laure Guenin-Macé, Jean-David Morel, Jean-Marc Doisne, Angèle Schiavo, Marie-Noëlle Ungeheuer, Thi Lam, Olivier Join-Lambert, James Di Santo, Aude Nassif, Caroline Demangel

The anaerobic microbiome of suppurative pilonidal sinus disease: another link with hidradenitis suppurativa (abstract ID 116)

Staphylococcus aureus carriage profile in hidradenitis suppurativa (HS) (abstract ID 138)
Dimitra Stergianou (Greece) Vassiliki Tzanetakou, Theodora Kanni, Amalia Bolanou, Evangelos J. Giamarellos-Bourboulis
Genetics and novel treatments (screen Epicurus)

Chair: Theodora Kanni (Greece)

A novel NCSTN gene mutation in a Japanese family with hidradenitis suppurativa (abstract ID 36)
Nobuyuki Nishimori (Japan), Koremasa Hayama, Kumiko Kimura, Hideki Fujita, Kyoko Fujiwara, Tadashi Terui

Adalimumab in Hurley II moderate-severe HS patients: Single center experience regarding disease non progression (abstract ID 61)
Fernando Alfageme Roldan (Spain), Hirune Cembrero, Constanza Martinez, Mercedes Sigüenza, Elena Lopez Negrete, Maria Antonia González de Domingo, Irene Salgüero, Gastón Roustan

Ixekizumab restores clinical response in patients with secondary loss of efficacy from adalimumab: results of a case series of 10 patients with hidradenitis suppurativa (abstract ID 107)
Caroline Hilbring (Germany), Gefion Girbig, Matthias Augustin, Natalia Kirsten

Baseline characteristics and burden of disease in patients with moderate to severe hidradenitis suppurativa enrolled in the SOLACE study – Final analysis (abstract 111)
Wayne Gulliver (Canada) Afsaneh Alavi, Kim Alexander Papp, Melinda J Gooderham, Olivier Desjardins, Christine Jean

Genome-wide association study of hidradenitis suppurativa in a multi-ethnic cohort Atlas (abstract ID 128)
Atlas Khan (USA), M. Geoffrey Hayes, John Connolly, Frank Mentch, Patrick Sleiman, Hakon Hakonarson, Joshua Denny, Chunhua Wang, George Hripcsak, Krzysztof Kiryluk, Lynn Petukhova
Decrease of pain and exacerbations by IFX-1 in severe hidradenitis suppurativa: An analysis using matched comparators (abstract ID 130)
Vassiliki Tzanetakou (Greece) Theodora Kanni, Maria Argyropoulou, Styliani Micha, Dimitra Stergianou, Amalia Bolanou, Evangelos J Giamarellos-Bourboulis

Adalimumab in conjunction with surgery in patients with moderate to severe hidradenitis suppurativa: baseline characteristics from a phase 4, double-blind, randomized, placebo-controlled study (abstract ID 132)
Falk G Bechara (Germany) Barbara Horváth, Gregor BE Jemec, Maurizio Podda, Errol P Prens, Ziqian Geng, Christine Jean, Christos C Zouboulis

Variability of TNFα expression in hidradenitis suppurativa (abstract ID 142)
Solene Gatault (Ireland) Sean Kearns, Helen Rea, Roisin Hambly, Walter Kolch, Brian Kirby

Lack of association of ATG16L1 single nucleotide polymorphisms on predisposition and severity of hidradenitis suppurativa (abstract 163)
Maria Mouktaroudi (Greece) Georgia Damoraki, Theodora Kanni, Maria Argyropoulou, Dimitra Stergianou, Amalia Bolanou, Vassiliki Tzanetakou, Evangelos J Giamarellos-Bourboulis
Medical treatment I (screen Asklepios)

Chair: George Kontochristopoulos (Greece)

Guselkumab in the treatment of patients with hidradenitis suppurativa: a case series (abstract ID 39)
Trinidad Montero-Vilchez (Spain), Carlos Cuenca-Barrales, Luis Salvador-Rodriguez, Antonio Martinez-Lopez, Salvador Arias-Santiago, Alejandro Molina-Leyva

Certolizumab pegol or brodalumab as reliable therapeutic option for coexisting hidradenitis suppurativa with psoriasis (abstract ID 40)
Eleftheria Tampouratzi (Greece) John Katsantonis

Successful treatment of pyoderma gangrenosum, acne, hidradenitis suppurativa and spondyloarthritis (PASS) syndrome with infliximab and methotrexate (abstract ID 50)
Juan Manuel Segura Palacios (Spain), Josefa Andrea Aguilar García, Carlos Romero Gómez, Magdalena de Troya Martín

PsAPSASH syndrome: a new phenotype of a hidradenitis suppurativa-related autoinflammatory syndrome treated with the IL-17A inhibitor secukinumab (abstract ID 51)
Georgios Nikolakis (Dessau, Germany), Katja Wolter, Aristeidis Vaiopoulos, Katarzyna Kaleta, Sumer Baroud, Christos C Zouboulis

Clinical evaluation of adalimumab biosimilar Imraldi in hidradenitis suppurativa (abstract ID 57)
Francesca Prignano (Italy), Elia Rosi, Maria Thais Fastame, Leonardo Pescitelli, Antonella Di Cesare, Federica Ricceri, Nicola Pimpinelli
Adalimumab dose deintensification in hidradenitis suppurativa (abstract ID 64)
Hirune Cembrero Saralegui (Spain) Fernando Alfageme Roldán, Lucia Turrión Merino, Rita Cabeza Martínez, Marta Elosua Gonzále, Gaston Roustán Gullón

The role of doxycycline and clindamycin in hidradenitis suppurativa: a prospective cohort study (abstract ID 67)
Carlos Cuenca-Barrales (Spain) Luis Salvador-Rodríguez, Salvador Arias-Santiago, Alejandro Molina-Leyva

Dapsone therapy for hidradenitis suppurativa (abstract ID 68)
Gregg Murray (Ireland), Aoife Hollywood, Brian Kirby, Rosalind Hughes

Experience of ustekinumab in the management of hidradenitis suppurativa (abstract ID 69)
Aoife Hollywood (Ireland), Gregg Murray, Brian Kirby, Rosalind Hughes

External evaluation of population pharmacokinetic model of adalimumab in patients with hidradenitis suppurativa (abstract ID 76)
Elena Gras-Colomer (Spain) Gregorio Martinez-Romero, Raúl Prats-Ortega, Antonio Martorell-Calatayud

Adalimumab dose intensification in recalcitrant hidradenitis suppurativa (abstract ID 85)
Christos C Zouboulis (Germany) Hendrik Hansen, Raffaele Dante Carosiena Caro, Giovanni Damiani, Isabelle Delorme, José Carlos Pascual, Ziad Regui, Anastasia Trigoni, Eva Vilarrasa, Fernando Alfageme Roldán
Medical treatment II (screen Hippocrates)
Chair: Ditte Marie Saunte (Denmark)

Paradoxical hidradenitis suppurativa in patients under TNF-alpha treatment: systematic review and therapeutic approach assessment (abstract ID 90)
Luis Salvador-Rodríguez (Spain), Carlos Cuenca-Barrales, Manuel Sánchez-Díaz, Trinidad Montero-Vílchez, Salvador Arias-Santiago, Alejandro Molina-Leyva

Identification of clinical categories in hidradenitis suppurativa based on patient characteristics: results from a cluster analysis (abstract ID 96)
Angelique Rondags (The Netherlands), Suzanne Arends, Rob J Volkering, Ineke C Janse, Janine L Dickinson-Blok, Eldrid Schoonhoven, Hendrika Bootsma, Anneke Spoorenberg, Barbara Horváth

Defining hidradenitis suppurativa phenotypes: results of a prospective study of 197 cases based on the elementary lesion pattern (abstract ID 99)
Antonio Martorell (Spain), Abdulhadi Jfri, Sterre Koster, Pilar Gómez-Palencia, Maria Solera, Alberto Alfaro-Rubio, Luis Hueso, Virginia Sanz-Motilva

Efficacy of adalimumab treatment in moderate to severe HS patients: real life data regarding quality of life improvement (abstract ID 113)
Anastasia Trigoni (Greece) Styliani Siskou, Elissavet Mingiani, Fragkiski Tsatsou, Elizabeth Lazaridou

The role of biologic therapy in special scenarios of hidradenitis suppurativa: facial HS, dissecting cellulitis of the scalp and HS lymphedema (abstract ID 117)
Manuel Sánchez-Díaz (Spain) Luis Salvador-Rodriguez, Trinidad Montero-Vilchez, Antonio Martínez-López, Salvador Arias-Santiago, Alejandro Molina-Leyva

Novel phenotype classification of hidradenitis suppurativa based upon clinical, ultrasonographical and analytical parameters. Part 1 (abstract ID 120)
Eva Vilarrasa (Spain), Eugenia Agut-Busquet, Silvia Vidal, Elisabet Cantó, Lluís Puig, Flavia Bittencourt

Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital (abstract ID 139)
Aikaterini Tsentemeidou (Greece) Eleni Sotiriou, Eustratios Vakirlis, Nikolaos Sideris, Aimilios Lallas, Dimitrios Ioannides

Azelaic acid and clindamycin for topical treatment of hidradenitis suppurativa – promising results of an open study (abstract ID 154)
Lennart Emtestam (Sweden), Hassan Killasli, Jan Lapins, Karin Sartorius

The efficacy of adalimumab therapy in recalcitrant hidradenitis suppurativa: Retrospective analysis (abstract ID 158)
Kagan Cingoz (Turkey) Kamer Gunduz, Gulsum Gencoglan, Cemal Bilac, Mustafa Turhan Sahin, Isil Inanir, Aylin Turel Ermertcan

TNF-α inhibitors and the risk of malignancy in patients with hidradenitis suppurativa: a case series (abstract ID 159)
Siobhan Carey (UK) Emelie Hutton, Sarah Walsh

Quality of life in patients with hidradenitis suppurativa treated with adalimumab (abstract ID 165)
Kleoniki Pantelidi (Greece), Efthymia Agiasofitou, Ioannis Marelakis, Anastasia Kapsiocha, Aikaterini Liakou, Nikolaos Rotsiamis, Georgios Kontochristopoulos, Dimitris Rigopoulos
Outcome measures I (screen Heraclitus)
Chair: Skaidra Valiukevičienė (Lithuania)

Updated hidradenitis suppurativa area and severity index (HASI): revised tool and psychometric assessment (abstract ID 27)
Noah Goldfarb (USA), Michelle A Lowes, Melissa Butt, Tonya King, Afsaneh Alavi, Joslyn S Kirby

Defining flare in HS: Latest results from an international Delphi study (abstract ID 28)
Joslyn Kirby (Belgium), Michaela Parnell, Athena Mammis-Gierbolini, Farida Benhadou, Véronique Del Marmol

Clinical response rates, placebo response rates and significantly associated covariates are dependent upon choice of outcome measure in hidradenitis suppurativa: A post-hoc analysis of PIONEER 1 and 2 individual patient data (abstract ID 32)
John W Frew (USA), Neha Singh, Caroline S Jiang, Kristina Navrazhina, David Grand, Roger Vaughan, James G Krueger

Development and validation of HSCAPS-1: a prediction model for diagnosis of hidradenitis suppurativa over cutaneous abscess (abstract ID 45)
Shari Wright (USA), Sarah Reddy, Joslyn Kirby, Andrew Strunk, Amit Garg

Validation of EQ-5D-5L, Skindex-16 and DLQI-R in comparison with Dermatology Life Quality Index in patients with hidradenitis suppurativa (abstract ID 54)
L. Hunor Gergely (Hungary), Krisztián Gáspár, Valentin Brodszky, Ágnes Kinyó, Andrea Szegedi, Éva Remenyik, Norbert F Kiss, Alex Bató, Márta Péntek, László Gulácsi, Miklós Sárda, András Bánvölgyi, Norbert Wikonkál, Fanni Rencz
**Novel phenotype classification of hidradenitis suppurativa based upon clinical, ultrasonographical and analytical parameters. Part 2 (abstract ID 81)**
Flavia Bittencourt (Spain), Eugenia Agut-Busquet, Silvia Vidal, Elisabet Cantó, Lluis Puig, Eva Vilarrasa

**Earlier onset of hidradenitis suppurativa in patients with multiple abscesses (abstract ID 93)**
Aikaterini I Liakou (Greece) Georgios Kontochristopoulos, Marios Papadakis, Ioannis Marelakis, Antigoni Alevizou, Efthymia Agiasofitou, Eleni-Georgia Kyriakaki, Dimitra Krystallaki, Dimitris Rigopoulos

**Vitamin D and its correlation with BMI and MEDAS score in patients with hidradenitis suppurativa – results of a unicentric cross-sectional study (abstract ID 106)**
Natalia Kirsten (Germany), Matthias Augustin, Caroline Hilbring, Gefion Girbig, F Neumann, J Sensen, Birgit-Christiane Zyriax

**Validation study of a new disease specific instrument to assess patient benefit from treatment by patients with hidradenitis suppurativa – HS-PBI (abstract ID 123)**
Natalia Kirsten (Germany), Falk G Bechara, Christine Blome, Andreas Pinter, Thomas Wild, Christos C Zouboulis, Matthias Augustin

**Predictive factors associated with response to adalimumab in patients with hidradenitis suppurativa (abstract ID 125)**
Raffaele Dante Caposiena Caro (Italy), Andrea Sechi, Marina Venturini, Elisa Molinelli, Valerio Brisigotti, Chiara Tartaglia, Beatrice Raone, Annalisa Patrizi, Piergiacomo Calzavara-Pinton, Annamaria Offidani, Luca Bianchi
Outcome measures II (screen Democritus)

Chair: Evgeniya Hristakieva (Bulgaria)

Therapeutic clinical-surgical strategy in window of opportunity - New surgical technique applied in fistulas (abstract ID 105)
Alberto Lavieri (Argentina), Claudio Greco, Emiliano Baccarini, GI Lopardo Villarino, Maria Florencia Vera Morandini

Combination of wide surgical excision with concomitant adalimumab treatment in 15 patients with Hurley III in a center in Northern Greece: sustained improvement in disease activity in severe HS patients. Our experience (abstract ID 108)
Anastasia Trigoni (Greece), Dimitrios Dionyssiou, Fragkiski Tsatsou, Styliani Siskou, Elissavet Mingiani, AntoniosTsimponis, Efterpi Demiri, Elizabeth Lazaridou

Intralesional ultrasound-guided treatment with steroid plus antibiotic therapy in hidradenitis suppurativa: a pilot study (abstract ID 115)
Luca Fania (Italy), Antonio Clemente, Francesca Sampogna, Cinzia Mazzanti, Sabatino Pallotta, Annarita Panebianco, Donatella Sordi, Alessio Caggiati, Gabriella Cassotta, Alessandro Tiezzi, Cristiano Lara, Viola Zecchi, Monica Napolitano, Damiano Abeni

Impact of carriage of Staphylococcus aureus in response to adalimumab in hidradenitis suppurativa (HS) (abstract ID 129)
Dimitra Stergianou (Greece) Vassiliki Tzanetakou, Maria Argyropoulou, Theodora Kanni, Evangelos J Giamarellos-Bourboulis

Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system (abstract ID 133)
Georgios Kokolakis (Germany) Kerstin Wolk, Sylke Schneider-Burrus, Stefanie Kalus, Sebasian Barbus, Susana Gomis-Kleindienst, Robert Sabat

*PG-like HS, a case series for introducing a new phenotype of HS (abstract ID 135)*
Evgeniya Hristakieva (Bulgaria) Karen Manuelyan, Tanya Gancheva, Rositsa Lavcheva, Radostina Deliyska

*Prevalence of neuropathic pain and related characteristics in hidradenitis suppurativa: preliminary data from a cross-sectional study (abstract ID 149)*
Simone Garcovich (Italy), Simona Muratori, Chiara Moltrasio, Agata Buscemi, Giulia Giovanardi, Dalma Malvaso, Enrico Di Stasio, Angelo Valerio Marzano, Ketty Peris

*The burden of eating disorders in HS patients is remarkable: A large database-based cohort study in the United States (abstract ID 151)*
Giovanni Damiani (Italy) Nicola Luigi Bragazzi, Haijiang Dai, Abdulla Watad, Mohammad Adawi, Paolo DM Pigatto

*NSAIDs and pain management in HS: important risk of flares (a series of 62 cases) (abstract ID 152)*
Pierre-André Bécherel (France), Marina Thomas, Jean-Christophe Moreno, Melani Dehais, Maia Delage, Aude Nassif

*Who will be Hurley III? (abstract ID 156)*
Mathieu Daoud (Belgium) Hassan Njimi, Mariano Suppa, Farida Benhadou, Gregor BE Jemec, Sara Saunte, Carmen Orte Cano, Véronique del Marmol
Hey Doc! I think I'm allergic to my sweat! Fox-Fordyce as a diagnostic challenge of hidradenitis suppurativa (abstract ID 42)
Farida Benhadou (Belgium) Valérie Chade-Tremeau, Nelly Youssef-Provençal, Philippe Guillem

Ehlers-Danlos syndrome, a very rare condition associated to hidradenitis suppurativa (abstract ID 43)
Farida Benhadou (Belgium) Philippe Guillem

Trends in body mass index before and after diagnosis of hidradenitis suppurativa (abstract ID 48)
Shari Wright (USA) Sarah Reddy, Andrew Strunk, Amit Garg

HS and intellectual disability: a possible syndromic condition (abstract ID 55)
Elia Rosi (Italy), Maria Thais Fastame, Leonardo Pescitelli, Antonella Di Cesare, Federica Ricceri, Lara Tripo, Nicola Pimpinelli, Francesca Prignano

The prevalence of nasal S. aureus amongst HS patients compared to healthy controls (abstract ID 62)
Khoa Manh Dinh (Denmark), Rune Kjærgaard Andersen, Christian Erikstrup, Paal Skytt Andersen, Susan Mikkelsen, Bertram Dalskov Kjerulf, Kristoffer Sølvsten Burgdorf, Thomas Folkmann Hansen, Kaspar Nielsen, Henrik Hjalgrim, Gregor BE Jemec, Henrik Ullum, Lise Tornvig Erikstrup, Ole Birger Pedersen

Early HS comorbidities based on an analysis of pharmaceutical prescriptions (abstract ID 63)
Rune Kjærsgaard Andersen (Denmark), Isabella Charlotte Loft, Gregor BE Jemec, Ole Birger Pedersen

A case of congenital generalized lipodystrophy associated with hidradenitis suppurativa (abstract ID 72)
Joel Reis (Portugal) Inês Lobo, Manuela Selores

Do childhood antibiotics predispose for HS development later in life? (abstract ID 74)
Rune Kjærsgaard Andersen (Denmark), Ditte Marie Saunte, Gregor BE Jemec

Hidradenitis suppurativa increases the risk of non-alcoholic fatty liver disease. A case control study (abstract ID 91)
José C Pascual (Spain), Iris González-Villanueva, Cristina De Gracia, Mariana Planells, José M Ramos, Pedro Álvarez, Luca Schneiller-Pavalescu

Earlier disease onset of hidradenitis suppurativa in patients with positive family history (abstract ID 92)
Aikaterini I Liakou (Greece) Georgios Kontochristopoulos, Ioannis Marmelakis, Marios Papadakis, Antigoni Alevizou, Nikolaos Rotsiamis, Maria Marouso Kyrgiopoulou, Dimitris Rigopoulos

Coexistence of hidradenitis suppurativa and acne fulminans in a newly described anti-inflammatory syndrome: ASH-syndrome (abstract ID 167)
Anastasia Kapsiocha (Greece) Efthymia Agiasofitou, Aikaterini I Liakou, Kleoniki Pantelidi, Ioannis Marmelakis, Dimitris Rigopoulos, Georgios Kontochristopoulos
Comorbidities II (screen Pythagoras)
Chair: Fragkiski Tsatsou (Greece)

Hidradenitis suppurativa surgical treatment – three years single center experience (abstract ID 65)
Piotr Krajewski (Poland) Karolina Wójcicka, Jacek C Szepietowski

Thyroid disease and active smoking are associated with more severe hidradenitis suppurativa (abstract ID 94)
Aikaterini I Liakou (Greece) Ioannis Marelakis, Antigoni Alevizou, Andreas G Tsantes, Marios Papadakis, Efthymia Agiasofitou, Georgios Kontochristopoulos, Dimitris Rigopoulos

Paradoxical psoriasis (abstract ID 121)
Alberto Lavieri (Argentina), Claudio Greco, Florencia Vera Morandini

Case Report: syndromal occurrence of severe hidradenitis suppurativa in a ten-year-old female patient with trisomy 13 (abstract ID 122)
Gefion Girbig (Germany), Caroline Hilbring, Matthias Augustin, Natalia Kirsten

PISH Syndrome: a new member of the syndromic suppurative hidradenitis network (abstract ID 143)
Vincenzo Bettoli (Italy), Valeria Scuderi, Riccardo Forconi, Natale Schettini, Pierantonia Zedde, Lucrezia Pacetti, Monica Corazza

KID syndrome and HS: a rare association responding to surgical treatment (abstract ID 144)
Vincenzo Bettoli (Italy), Riccardo Forconi, Ilaria Pezzini, Ruby Martinello, Valeria Scuderi, Pierantonia Zedde, Natale Schettini, Lucrezia Pacetti, Monica Corazza
Carcinoma cuniculatum arising within hidradenitis suppurativa (abstract ID 145)
Daniel Falkenhain López (Spain) Alba Sánchez-Velázquez, Alba López Valle, Jon F Barbarin, Mario Puerta-Peña, Verónica Monsálvez Honrubia

Rare onset of hidradenitis suppurativa 11 years after menopause: case report (abstract ID 148)
Corina Ioana Cucu (Romania) Raluca Miulescu, Liliana Popa, Mara Mihai, Olguta Orzan

Obstructive sleep apnea in hidradenitis suppurativa and psoriasis (abstract ID 157)
Aine Kelly (Ireland), Shivashini Kirithi, Caitriona Ryan, Rosalind Hughes, John Garvey, Brian Kirby

Association between acne conglobata and hidradenitis suppurativa in a male patient (abstract ID 161)
Cristina Vajaitu (Romania), Alexandra Dorobantu, Vlad Mihai Voiculescu, Olguta Anca Orzan

Fecal calprotectin: a promising biomarker regarding the coexistence of hidradenitis suppurativa and inflammatory bowel disease (abstract ID 168)
Georgios Kontochristopoulos (Greece) Anastasia Kapsiocha, Efthymia Agiasofitou, Ioannis Marnelakis, Aikaterini I Liakou, Kleoniki Pantelidi, Nikolaos Rotsiamis, Dimitris Rigopoulos
Industry sponsored events

**Wednesday February 5, 2020**

**13:00-15:00 Abbvie sponsored workshop (Olympia Hall)**

**Integrated Medical & Surgical Treatment in HS**

Chairs: Falk G Bechara (Germany), Philippe Guilliem (France)

The aim of this surgical workshop is to underline the need for adequate combination of medical and surgical techniques in the treatment of HS patients. The workshop is including lectures on different surgical questions and challenges in daily routine, as well as an interactive part. Within the interactive part the faculty will present real-life cases and postoperative surgical situations. These are discussed with the audience, who are also encouraged to send their cases which can be evaluated together.

- **What are we talking about? The problem of missing technical definitions and terms of recurrence**  
  Phillipe Guilliem (France)

- **Medical downsizing before surgery: When, how and why?**  
  Stephanie R Goldberg (USA)

- **Treatment of genital lymphedema: Medical, surgical, or both?**  
  Falk G Bechara (Germany)

**My complex cases: What is your solution?**

Faculty and Audience

*Complex cases including medical history and previous treatments are presented by the faculty. Treatments plans and strategies are then discussed in an interactive setting with the audience*

**Close or not to close, that is the question!**

Faculty and Audience

*Intra- and postoperative surgical situations are discussed. A variety of different defects at different locations are presented. Together with the audience, Pro'S and Con's of secondary intention healing and closure techniques are discussed. Surgical solution that have been found are discussed and long-term outcomes are shown and discussed by the faculty and audience.*
Friday February 7, 2020
11:00-12:30 AbbVie Satellite Symposium (Olympia Hall)
New horizons in the management of hidradenitis suppurativa

AbbVie Satellite Symposium (Olympia Hall)

Participants: Falk G Bechara (Germany), Antonio Martorell-Catalayud (Spain), Thrasyvoulos Tzellos (Norway)

Key take-home message
- The knowledge around optimal management of hidradenitis suppurativa (HS) is evolving, and we are looking at a new horizon for care, where integrated therapies can be managed effectively for the majority of patients

Learning objectives
- Highlight the evolution in HS management over a relatively short space of time, and what we've learned along the way
- Use case profiles to describe how patients were being treated 10 years ago and how we would manage them today, including medical only, surgery only, and combined therapy
- Emphasize remaining uncertainties in how to optimally combine medical and surgical therapy and what new information the SHARPS study is bringing
- Discuss what the future standard of care for HS may look like, including emerging molecular targets and pipeline therapies
**General Information**

The registration desk will be at the Olympia Exhibition Hall.

Wednesday 5th February: 09:00-15:00  
Thursday 6th February: 08:00-18:00  
Friday 7th February: 09:00-17:00

**Badges** should be worn during scientific and social events. You can be asked to show your badge for the entrance to the Opening Ceremony – National and Kapodistrian University of Athens and Conference Dinner at the Acropolis Museum.

**Certificates of attendance** will be sent via email after the end of the Conference.

**Poster Service** – ePoster session will be located at Ilissos Hall.

---

**Wednesday 5th February 2020**

Opening Ceremony & Plenary Programme  
Auditorium of the Old Building of the National and Kapodistrian University of Athens  
Bus transfer from Divani Caravel Hotel at 15:15.
Welcome reception at Kostis Palamas building
Walking distance from National and Kapodistrian University of Athens. The neoclassical building “Kostis Palamas” was inaugurated in 1857 and initially, it operated as a private Lyceum with the name “Greek Educational Establishment”. It was renovated in 2004 with the funding of the “Stavros Niarhos” Institute and since then, it has operated as a Cultural Centre – Lounge.

Acropolis Museum
Guided tour at the Acropolis Museum at 19:00. Dinner at Acropolis museum restaurant at 20:00. Transfer from Divani Caravel Hotel at 18:15.
Conference Venue
Divani Caravel Hotel
2, Vas. Alexandrou ave, 12161 Athens // Tel: +302107207000

The Divani Caravel Hotel, member of the Leading Hotels of the World, enjoys a prime location in the heart of this iconic city making it the ideal location to visit Athens major attractions.
Project: **EHSF 2020**  
9th Conference of the European Hidradenitis Suppurativa Foundation

Dimitra Athanasia Litsardou  
Architect - 3rd Class Construction Engineer | MSc - PhD(c) Urban and Regional Planning NTUA  
+30 6946065806 | email: dlitsardou@gmail.com

**Conference venue**  
**Ilissos** floor plan

1. e-posters  
2. Exhibition area  
3. Relax space  
4. Conference information  
5. Restaurant

**Conference venue**  
**Olympia** floor plan

6. Conference hall  
7. Conference information  
8. Speakers' helpdesk  
9. Speakers' room  
10. Exhibition area
Our Sponsors

Platinum Sponsor

abbvie

Silver Sponsor

NOVARTIS

Sponsor

Biogen

FARAN

HidraMed Solutions

inflaRx

Lilly

InterMed

ZERO GRAVITY
Reimagining Immunodermatology

9th Conference of the European Hidradenitis Suppurativa Foundation
5–7 February 2020

Please join us at the Novartis medical booth to discover how we are exploring dermatological disease pathways, and bringing the future of Immunodermatology to life.

Visit us at Booth A in the exhibition hall located in Iliissos Foyer (Ground Floor).

Novartis looks forward to seeing you there.
Contact
Organizing PCO
Imagine Congress & Travel
9, Kolokotroni st
10562 Athens, Greece
Phone +30 2103252520
Ms Vana Antonopoulou
v.antonopoulou@otenet.gr
www.imaginecongress.gr

Official site
www.ehsf2020.com, E-mail:info@ehsf2020.com